EATRIS Combined Platform Meeting
|Date & Time||December 11 - 12th, 2018|
The 2018 EATRIS Combined Platform Meeting will be held in Ljubljana on December 11th and 12th. Like in previous years, the Platform Combined Meeting will be the moment to discuss the EATRIS platform activities and future strategies together, providing formidable networking opportunities. This year the Platform Combined Meeting will also be followed by a two-day CORBEL open workshop on the theme of public-private collaboration. This 2-day event on 12th and 13th December 2018 (back to back with the Combined EATRIS Platform meeting in Ljubljana) will focus on all relevant aspects of setting up such collaborations, from initial contacts through planning and negotiation to completion of legal agreements and project implementation.
Provisional Schedule of the Combined Platform Meeting
Tuesday 11th December
09.30 – 12.30 Plenary session
– Present and Future of EATRIS
12.30 – 13.30 Lunch
13.30 – 17.30 Break-out sessions
17.30 – 19.00 Networking drinks & Poster session
19.30 – 22.00 Networking dinner at the Grand Union Hotel restaurant
Wednesday 12th December
09.00 – 12.00 Plenary session
– Feedback from the break-out sessions
– EATRIS positioning & action agenda for the platforms
12.00 – 13.00 Lunch
13.00 – 13.45 Plenary session
– EATRIS implementation of operations at the national level
13.45 – 14.00 Closing remarks
14.00 – 16.00 Strategy meeting (EATRIS National Directors and Platform Chairs only)
With regards to accomodation, we have reserved a block of rooms at the Grand Union Hotel at a discounted rate starting from 115€ per night. Reserve now your Business room (115€) or your Comfort room (135€).
Travel and accommodation reimbursement can be submitted after the meeting, up to 250€ for one person per platform per institution. The fund is limited and each submission is subject to review prior proceeding. To submit your reimbursement, please contact email@example.com before January 18th 2019.
An integrated understanding of mechanisms underlying disease phenomena can create new opportunities for therapeutic development. The modern translational research toolbox is maturing with multi-modal technologies that allow deep investigation of integrated biological systems and pathways rather than looking at isolated targets. For example, early clinical trials using whole body (multimodal) and functional imaging can provide key insights for target engagement, PK/PD or dosing to help predicting R&D success at early stage. In silico analysis, machine learning and artificial intelligence approaches may lead to new insights and hypotheses that can ultimately result in novel molecular tools and drug candidates. This session aims to illustrate how these emerging platforms can bring a profound understanding of mechanism of action and target validation.
Through sharing case studies, we intend to define for EATRIS:
- What is the current state of the art of ‘disease mapping’ approaches, within EATRIS and beyond
- What are key determinants for the predictive value of a specific model
- How to achieve the highest translational potential for successful molecular intervention
Description: Immune Cell therapy represents a revolutionary treatment for hematological malignancies evidenced by the recent breakthrough successes involving CAR-T therapies for B-Cell Leukemias. The success of this type of treatment however has not yet been realized in solid tumors. One hypothesis is that the immunosuppressive nature of the tumor microenvironment (TME) influences and affects the efficacy of adoptive immunotherapy. Understanding the role of the TME and its interaction with immune cell therapies is key to improve the potency of adoptive immunotherapy. These include identifying multimodal approaches to monitoring the limited trafficking of adoptively transferred cells to tumor sites, the identification of proper tumor associated antigen and a greater understanding of the immunosuppressive effect of the tumor microenvironment. This session will discuss innovative multimodal approaches to immunomodulation and immunomonitoring to ensure the safest and most effective combinations of therapeutic modalities for patients with solid tumors.
Description: Development of biomarkers for patient stratification is a vital concept to facilitate the development and implementation of personalized medicines.
Multimodal biomarker approaches integrating various technologies (omics, imaging, functional readouts) are key in the development of high quality stratification biomarkers to enable personalized medicine diagnosis, prognosis and prediction of treatment effectiveness.
The session will highlight the current achievements and challenges in patient stratification biomarker R&D. Through sharing examples, we intend to define our best practice within EATRIS on the following key issues:
- Technology push vs clinical pull
- Approaches to combine multi-omics approaches
- Quality, harmonization, standardization & reproducibility
- Follow-up translation to product